Sign up to save your podcasts
Or
Share Episode 505 : ASCO 2026 - RAMPART
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 505 : ASCO 2026 - RAMPART
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
View all episodes
By The Uromigos
4.9
5757 ratings
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
More shows like The Uromigos
View all
TED Radio Hour
21,954 Listeners
Freakonomics Radio
32,246 Listeners
Planet Money
30,609 Listeners
JAMA Clinical Reviews
504 Listeners
Behind The Knife: The Surgery Podcast
1,309 Listeners
Prostate Cancer Update
14 Listeners
ASCO Daily News
59 Listeners
The Diary Of A CEO with Steven Bartlett
8,876 Listeners
OncLive® On Air
23 Listeners
GU Cast | Urology Podcast
2 Listeners
Oncology Today with Dr Neil Love
59 Listeners
People I (Mostly) Admire
2,030 Listeners
ZOE Science & Nutrition
2,131 Listeners
Two Onc Docs
195 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
45 Listeners